4883 — Modalis Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Modalis Therapeutics, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.1 | 40.5 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 757 | 2,815 | 2,409 | 1,351 | 2,214 |
| Operating Profit | -756 | -2,775 | -2,409 | -1,351 | -2,214 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -745 | -2,707 | -2,391 | -1,317 | -2,151 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -739 | -2,703 | -2,392 | -1,318 | -2,153 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -739 | -2,703 | -2,392 | -1,318 | -2,153 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -739 | -2,703 | -2,392 | -1,318 | -2,153 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -36.6 | -77 | -76.4 | -28.4 | -27.8 |
| Dividends per Share |